3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Neoplasms
18
Breast Neoplasms
17
Prostatic Neoplasms
10
Colorectal Neoplasms
9
Lung Neoplasms
8
Hematologic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Hematopoietic and Lymphatic System Neoplasm
5
Urinary Bladder Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Anatomic Stage I Breast Cancer AJCC v8
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Mouth Neoplasms
3
Melanoma
3
Malignant Solid Neoplasm
3
Sarcoma
2
Parotid Neoplasms
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Myelodysplastic Syndromes
2
Head and Neck Carcinoma
2
Glioma
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Standard of Care
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled